Inify Laboratories - Annual Report 2025

15 Apr 2026 08:43 CEST

Stockholm – April 15, 2026 – Inify Laboratories, a unique laboratory service
provider within pathology and cancer diagnostics, presents its Annual Report for
the fiscal year ended December 31, 2025.

The annual report is attached to this press release and is also available on the
company’s website: www.inify.com.

Printed copies of the report will be distributed upon request sent to e-mail:
ir@inify.com.

For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail:
ann-charlotte.linderoth@inify.com or: ir@inify.com


###


About Inify Laboratories

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.


Quality and response times are optimised in every step – from logistics to
tissue preparation and diagnosis – using a fully digital, standardised and
AI-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.


Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo under the ticker INIFY.


This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

670645_Inify Laboratories Annual Report 2025.pdf